The muscarinic system, cognition and schizophrenia

Neuroscience and Biobehavioral Reviews

Volumn 55, Issue , 2015, Pages 393-402

  Carruthers, Sean P ^a,b   Gurvich, Caroline T ^b   Rossell, Susan L ^a,b,c  

^a SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^b Australia   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

Acetylcholine; Anti muscarinic psychosis; Anti muscarinic Syndrome; Attention; Cholinergic; Cognition; Executive functioning; Learning; M1 receptor; M4 receptor; Memory; Muscarinic; Psychosis; Schizophrenia; Xanomeline

Indexed keywords

CLOZAPINE; GSK 1034702; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M2 RECEPTOR; NORCLOZAPINE; UNCLASSIFIED DRUG; VU 0467154; VU 1052100; XANOMELINE; ACETYLCHOLINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; MUSCARINIC RECEPTOR;

CHOLINERGIC SYSTEM; COGNITION; DISEASE ASSOCIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; HUMAN; MUSCARINIC SYSTEM; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME; ANIMAL; BRAIN; DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY;

ACETYLCHOLINE; ANIMALS; BRAIN; CHOLINERGIC AGENTS; COGNITION; HUMANS; RECEPTORS, MUSCARINIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84930942652     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2015.05.011     Document Type: Review

References (178)

1. Abi-Dargham A., Mawlawi O., Lombardo I., Gil R., Martinez D., Huang Y., et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J. Neurosci. 2002, 22(9):3708-3719.
2. Andersen M.B., Fink-Jensen A., Peacock L., Gerlach J., Bymaster F., Lundbaek J.A., Werge T. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology 2003, 28(6):1168-1175. (official publication of the American College of Neuropsychopharmacology).
3. Andrus A.K., Marable B.R., Dunbar G.L., Reilly M.P., Maurissen J.P.J. Effects of intensity and type of prepulse stimulus on prepulse inhibition in scopolamine treated rats. Pharmacol. Biochem. Behav. 2007, 87(4):481-488. 10.1016/j.pbb.2007.06.004.
4. Anon ACADIA Pharmaceuticals Announces Results from ACP-104 Phase IIb Schizophrenia Trial 2008, 〈http://www.drugs.com/clinical_trials/acadia-pharmaceuticals-announces-results-acp-104- phase-iib-schizophrenia-trial-4810.html#ixzz0naCBgfBh〉 (accessed 2014).
5. Barak S. Modeling cholinergic aspects of schizophrenia: focus on the antimuscarinic syndrome. Behav. Brain Res. 2009, 204(2):335-351. 10.1016/j.bbr.2009.04.006.
6. Barak S., Weiner I. Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor. Neuropsychopharmacology 2007, 32(5):989-999. 10.1038/sj.npp.1301208.
7. Barak S., Weiner I. Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs. Int. J. Neuropsychopharmacol. 2009, 12(2):227-241. 10.1017/S1461145708009176.
8. Barak S., Weiner I. Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine. Psychopharmacology 2010, 209(2):175-184. 10.1007/s00213-010-1785-z.
9. Barak S., Weiner I. Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target. Pharmacol. Biochem. Behav. 2011, 99(2):164-189. 10.1016/j.pbb.2011.03.011.
10. Barak S., Weiner I. The M 1/M 4 preferring agonist xanomeline reverses amphetamine-, MK801-and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia. Int. J. Neuropsychopharmacol. 2011, 14(9):1233-1246.
11. Bilder R.M., Goldman R.S., Volavka J., Czobor P., Hoptman M., Sheitman B., et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry 2002, 159(6):1018-1028.
12. Bodick N.C., Offen W.W., Levey A.I., Cutler N.R., Gauthier S.G., Satlin A., et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol. 1997, 54(4):465-473.
13. Bodick N.C., Offen W.W., Shannon H.E., Satterwhite J., Lucas R., Van Lier R., Paul S.M. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis. Assoc. Dis. 1997, 11(SUPPL. 4):S16-S22.
14. Bonner T.I., Buckley N.J., Young A.C., Brann M.R. Identification of a family of muscarinic acetylcholine receptor genes. Science 1987, 237(4814):527-532.
15. Bonner T.I., Young A.C., Bran M.R., Buckley N.J. Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1988, 1(5):403-410.
16. Bowie C.R., Reichenberg A., Patterson T.L., Heaton R.K., Harvey P.D. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am. J. Psychiatry 2006, 163(3):418-425.
17. Bradford A.M., Savage K.M., Jones D.N.C., Kalinichev M. Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics. Psychopharmacology 2010, 212(2):155-170.
18. Bradley S.R., Lameh J., Ohrmund L., Son T., Bajpai A., Nguyen D., et al. AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology 2010, 58(2):365-373.
19. Brady A.E., Jones C.K., Bridges T.M., Kennedy J.P., Thompson A.D., Heiman J.U., et al. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J. Pharmacol. Exp. Ther. 2008, 327(3):941-953.
20. Bridges T.M., Kennedy J.P., Cho H.P., Breininger M.L., Gentry P.R., Hopkins C.R., et al. Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M5 PAM. Bioorg. Med. Chem. Lett. 2010, 20(2):558-562.
21. Brown Jordan W., Rueter Lynne E., Zhang Min. Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2014, 49(0):53-62. http://dx.doi.org/10.1016/j.pnpbp.2013.11.008.
22. Bryson G., Bell M.D. Initial and final work performance in schizophrenia: cognitive and symptom predictors. J. Nervous Mental Dis. 2003, 191(2):87-92.
23. Bubser M., Bridges T.M., Dencker D., Gould R.W., Grannan M., Noetzel M.J., et al. Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents. ACS Chem. Neurosci. 2014, 5(10):920-942.
24. Buchanan K.A., Petrovic M.M., Chamberlain S.E.L., Marrion N.V., Mellor J.R. Facilitation of long-term potentiation by Muscarinic M1 receptors is mediated by inhibition of SK channels. Neuron 2010, 68(5):948-963.
25. Bymaster F.P., Felder C.C. Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents. Mol. Psychiatry 2002, 7(Suppl. 1):S57-S63.
26. Byun N.E., Grannan M., Bubser M., Barry R.L., Thompson A., Rosanelli J., et al. Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100. Neuropsychopharmacology 2014, 39(7):1578-1593.
27. Chambon C., Jatzke C., Wegener N., Gravius A., Danysz W. Using cholinergic M1 receptor positive allosteric modulators to improve memory via enhancement of brain cholinergic communication. Eur. J. Pharmacol. 2012, 697(1-3):73-80.
28. Chambon C., Wegener N., Gravius A., Danysz W. A new automated method to assess the rat recognition memory: validation of the method. Behav. Brain Res. 2011, 222(1):151-157.
29. Chan W.Y., McKinzie D.L., Bose S., Mitchell S.N., Witkin J.M., Thompson R.C., et al. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc. Nati. Acad. Sci. U.S.A. 2008, 105(31):10978-10983.
30. Chintoh A., Fulton J., Koziel N., Aziz M., Sud M., Yeomans J.S. Role of cholinergic receptors in locomotion induced by scopolamine and oxotremorine-M. Pharmacol. Biochem. Behav. 2003, 76(1):53-61. 10.1016/S0091-3057(03)00196-5.
31. Clarke L.A., Cassidy C.W., Catalano G., Catalano M.C., Carroll K.M. Psychosis induced by smoking cessation clinic administered anticholinergic overload. Ann. Clin. Psychiatry 2004, 16(3):171-175. 10.1080/10401230490487034.
32. Conn P.J., Jones C.K., Lindsley C.W. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol. Sci. 2009, 30(3):148-155.
33. Crook J.M., Tomaskovic-Crook E., Copolov D.L., Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol. Psychiatry 2000, 48(5):381-388.
34. Crook J.M., Tomaskovic-Crook E., Copolov D.L., Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am. J. Psychiatry 2001, 158(6):918-925.
35. Daban C., Martinez-Aran A., Torrent C., Tabarés-Seisdedos R., Balanzá-Martínez V., Salazar-Fraile J., et al. Specificity of cognitive deficits in bipolar disorder versus schizophrenia: a systematic review. Psychother. Psychosomatics 2006, 75(2):72-84.
36. Davie B.J., Christopoulos A., Scammells P.J. Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits. ACS Chem. Neurosci. 2013, 4(7):1026-1048.
37. Dean B. Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia. Curr. Pharm. Biotechnol. 2012, 13(8):1563-1571.
38. Dean B., McLeod M., Keriakous D., McKenzie J., Scarr E. Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol. Psychiatry 2002, 7(10):1083-1091.
39. Dean B., Soulby A., Evin G.M., Scarr E. Levels of [3H]pirenzepine binding in Brodmann's area 6 from subjects with schizophrenia is not associated with changes in the transcription factor SP1 or BACE1. Schizophrenia Res. 2008, 106(2-3):229-236.
40. Dencker D., Weikop P., Sørensen G., Woldbye D.P.D., Wörtwein G., Wess J., Fink-Jensen A. An allosteric enhancer of M4 muscarinic acetylcholine receptor function inhibits behavioral and neurochemical effects of cocaine. Psychopharmacology 2012, 224(2):277-287.
41. Dencker D., Wörtwein G., Weikop P., Jeon J., Thomsen M., Sager T.N., et al. Involvement of a subpopulation of neuronal M 4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M 1/M 4 preferring muscarinic receptor agonist xanomeline. J. Neurosci. 2011, 31(16):5905-5908.
42. Deng C., Huang X.F. Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia. J. Neurosci. Res. 2005, 81(6):883-890.
43. Desmarais J.E., Beauclair L., Margolese H.C. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment?. J. Psychopharmacol. 2012, 26(9):1167-1174.
44. Désaméricq G., Schurhoff F., Meary A., Szöke A., Macquin-Mavier I., Bachoud-Lévi A.C., Maison P. Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. Eur. J. Clin. Pharmacol. 2014, 70(2):127-134. 10.1007/s00228-013-1600-y.
45. Eglen R.M. Muscarinic receptor subtype pharmacology and physiology. Prog. Med. Chem. 2005, 43:105-136.
46. Eglen R.M. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Autonomic Autacoid Pharmacol. 2006, 26(3):219-233.
47. Espinoza-Fonseca L.M., Trujillo-Ferrara J.G. Identification of multiple allosteric sites on the M1 muscarinic acetylcholine receptor. FEBS Lett. 2005, 579(30):6726-6732.
48. Fiszdon J.M., Choi J., Goulet J., Bell M.D. Temporal relationship between change in cognition and change in functioning in schizophrenia. Schizophrenia Res. 2008, 105(1-3):105-113.
49. Flynn D.D., Ferrari-DiLeo G., Mash D.C., Levey A.I. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J. Neurochem. 1995, 64(4):1888-1891.
50. Foster D.J., Choi D.L., Conn P., Rook J.M. Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia. Neuropsychiatr. Dis. Treat. 2014, 10:183-191.
51. Galloway C.R., Lebois E.P., Shagarabi S.L., Hernandez N.A., Manns J.R. Effects of Selective activation of m1 and m4 muscarinic receptors on object recognition memory performance in rats. Pharmacology 2014, 93(1-2):57-64.
52. Gholamreza P., Pratt J.A., Nima D. Effects of low-dose scopolamine on locomotor activity: no dissociation between cognitive and non-cognitive effects. Neurosci. Res. Commun. 2002, 31(3):165-174. 10.1002/nrc.10049.
53. Gibbons A.S., Scarr E., Boer S., Money T., Jeon W.J., Felder C., Dean B. Widespread decreases in cortical muscarinic receptors in a subset of people with schizophrenia. Int. J. Neuropsychopharmacol. 2013, 16(1):37-46.
54. Ginovart N., Kapur S. Role of dopamine D2 receptors for antipsychotic activity. Handbook Exp. Pharmacol. 2012, 212:27-52.
55. Göpel C., Laufer C., Marcus A. Three cases of angel's trumpet tea-induced psychosis in adolescent substance abusers. Nordic J. Psychiatry 2002, 56(1):49-52. 10.1080/08039480252803927.
56. Gotti C., Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog. Neurobiol. 2004, 74(6):363-396.
57. Gotti C., Zoli M., Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol. Sci. 2006, 27(9):482-491.
58. Granacher R.P., Baldessarini R.J. Physostigmine. Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs. Arch. Gen. Psychiatry 1975, 32(3):375-380.
59. Green A., Ellis K.A., Ellis J., Bartholomeusz C.F., Ilic S., Croft R.J., et al. Muscarinic and nicotinic receptor modulation of object and spatial n-back working memory in humans. Pharmacol. Biochem. Behav. 2005, 81(3):575-584.
60. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the 'right stuff'?. Schizophrenia Bull. 2000, 26(1):119-136.
61. Green M.F., Kern R.S., Heaton R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophrenia Res. 2004, 72(1):41-51.
62. Hagger C., Buckley P., Kenny J.T., Friedman L., Ubogy D., Meltzer H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry 1993, 34(10):702-712.
63. Han M., Newell K., Zavitsanou K., Deng C., Huang X.F. Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain. J. Neurosci. Res. 2008, 86(2):457-464.
64. Henny P., Jones B.E. Projections from basal forebrain to prefrontal cortex comprise cholinergic, GABAergic and glutamatergic inputs to pyramidal cells or interneurons. European J. Neurosci. 2008, 27(3):654-670.
65. Holland M.S. Central anticholinergic syndrome in a pediatric patient following transdermal scopolamine patch placement. Nurse Anesth. 1992, 3(3):121-124.
66. Holzgrabe U., Bender W., Botero Cid H.M., Staudt M., Pick R., Pfletschinger C., et al. Ligands for the common allosteric site of acetylcholine M2-receptors: development and application. Pharm. Acta Helvetiae 2000, 74(2-3):149-155.
67. Howes O.D., Egerton A., Allan V., McGuire P., Stokes P., Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr. Pharm. Des. 2009, 15(22):2550-2559.
68. Ibrahim H.M., Tamminga C.A. Schizophrenia: treatment targets beyond monoamine systems. Ann. Rev. Pharmacol. Toxicol. 2011, 51:189-209.
69. Ibrahim H.M., Tamminga C.A. Treating impaired cognition in schizophrenia. Curr. Pharm. Biotechnol. 2012, 13(8):1587-1594.
70. Iversen L.L., Iversen S.D., Bloom F.E., Roth R.H. Introduction to Neuropsychopharmacology 2009, Oxford University Press, New York, NY.
71. Jeon J., Dencker D., Wörtwein G., Woldbye D.P.D., Cui Y., Davis A.A., et al. A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors. J. Neurosci. 2010, 30(6):2396-2405.
72. Jones C.K., Brady A.E., Davis A.A., Xiang Z., Bubser M., Tantawy M.N., et al. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J. Neurosci. 2008, 28(41):10422-10433.
73. Jones C.K., Eberle E.L., Shaw D.B., McKinzie D.L., Shannon H.E. Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats. J. Pharmacol. Exp. Ther. 2005, 312(3):1055-1063.
74. Jooste E.H., Sharma A., Zhang Y., Emala C.W. Rapacuronium augments acetylcholine-induced bronchoconstriction via positive allosteric interactions at the M3 muscarinic receptor. Anesthesiology 2005, 103(6):1195-1203.
75. Kahn R.S., Keefe R.S.E. Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry 2013, 70(10):1107-1112.
76. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45(9):789-796.
77. Keefe R.S.E., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch. Gen. Psychiatry 2007, 64(6):633-647.
78. Keefe R.S.E., Fenton W.S. How should DSM-V criteria for schizophrenia include cognitive impairment?. Schizophrenia Bull. 2007, 33(4):912-920.
79. Kennedy J.P., Bridges T.M., Gentry P.R., Brogan J.T., Kane A.S., Jones C.K., et al. Synthesis and structure-activity relationships of allosteric potentiators of the M4 muscarinic acetylcholine receptor. ChemMedChem 2009, 4(10):1600-1607.
80. Kim H.S., Shin N.Y., Jang J.H., Kim E., Shim G., Park H.Y., et al. Social cognition and neurocognition as predictors of conversion to psychosis in individuals at ultra-high risk. Schizophrenia Res. 2011, 130(1-3):170-175.
81. Klinkenberg I., Blokland A. The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci. Biobehav. Rev. 2010, 34(8):1307-1350.
82. Kraepelin E. Dementia Praecox and Paraphrenia 1919, Livingstone, Edinburgh.
83. Kubo T., Fukuda K., Mikami A., Maeda A., Takahashi H., Mishina M., et al. Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature 1986, 323(6087):411-416.
84. Lanzafame A.A., Christopoulos A., Mitchelson F. Cellular signaling mechanisms for muscarinic acetylcholine receptors. Receptors Channels 2003, 9(4):241-260.
85. Le U., Melancon B.J., Bridges T.M., Vinson P.N., Utley T.J., Lamsal A., et al. Discovery of a selective M4 positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia. Bioorg. Med. Chem. Lett. 2013, 23(1):346-350.
86. Leach K., Loiacono R.E., Felder C.C., McKinzie D.L., Mogg A., Shaw D.B., et al. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 2010, 35(4):855-869.
87. Lebois E.P., Bridges T.M., Lewis L.M., Dawson E.S., Kane A.S., Xiang Z., et al. Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M1 receptor function in the central nervous system. ACS Chem. Neurosci. 2010, 1(2):104-121.
88. Lendvai B., Kassai F., Szájli T., Némethy Z. α7 Nicotinic acetylcholine receptors and their role in cognition. Brain Res. Bull. 2013, 93:86-96.
89. Lencz T., Smith C.W., McLaughlin D., Auther A., Nakayama E., Hovey L., Cornblatt B.A. Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol. Psychiatry 2006, 59(9):863-871.
90. Lenz W., Petrusch C., Jakobs K.H., Van Koppen C.J. Agonist-induced down-regulation of the m4 muscarinic acetylcholine receptor occurs without changes in receptor mRNA steady-state levels. Naunyn-Schmiedeberg's Arch. Pharmacol. 1994, 350(5):507-513.
91. Levey A.I. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci. 1993, 52(5-6):441-448.
92. Levey A.I., Edmunds S.M., Heilman C.J., Desmond T.J., Frey K.A. Localization of muscarinic M3 receptor protein and M3 receptor binding in rat brain. Neuroscience 1994, 63(1):207-221.
93. Levey A.I., Kitt C.A., Simonds W.F., Price D.L., Brann M.R. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J. Neurosci. 1991, 11(10):3218-3226.
94. Lewandowski K.E., Cohen B.M., Öngur D. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychol. Med. 2011, 41(2):225-241.
95. Lewis R. Should cognitive deficit be a diagnostic criterion for schizophrenia?. J. Psychiatry Neurosci. 2004, 29(2):102-113.
96. Li Z., Huang M., Ichikawa J., Dai J., Meltzer H.Y. N-Desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology 2005, 30(11):1986-1995.
97. Liao C., Themmen A., Joho R., Barberis C., Birnbaumer M., Birnbaumer L. Molecular cloning and expredsion of a fifth muscarinic acetylcholine receptor. J. Biol. Chem. 1989, 264(13):13.
98. Liao D.L., Hong C.J., Chen H.M., Chen Y.E., Lee S.M., Chang C.Y., et al. Association of muscarinic M1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients. Neuropsychobiology 2003, 48(2):72-76.
99. Logue S.F., Gould T.J. The neural and genetic basis of executive function: attention, cognitive flexibility, and response inhibition. Pharmacol. Biochem. Behav. 2014, 123:45-54.
100. Lucas-Meunier E., Fossier P., Baux G., Amar M. Cholinergic modulation of the cortical neuronal network. Pflugers Arch. Eur. J. Physiol. 2003, 446(1):17-29.
101. Ma L., Seager M., Wittmann M., Jacobson M., Bickel D., Burno M., et al. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(37):15950-15955.
102. Mathur A., Shandarin A., Laviolette S.R., Parker J., Yeomans J.S. Locomotion and stereotypy induced by scopolamine: contributions of muscarinic receptors near the pedunculopontine tegmental nucleus. Brain Res. 1997, 775(1-2):144-155. 10.1016/S0006-8993(97)00928-1.
103. Mancama D., Arranz M.J., Landau S., Kerwin R. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am. J. Med. Genet.-Neuropsychiatr. Genet. 2003, 119(B(1)):2-6.
104. Melancon B.J., Hopkins C.R., Wood M.R., Emmitte K.A., Niswender C.M., Christopoulos A., et al. Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J. Med. Chem. 2012, 55(4):1445-1464.
105. Meltzer H.Y. Treatment-resistant schizophrenia-the role of clozapine. Curr. Med. Res. Opin. 1997, 14(1):1-20.
106. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bull. 1999, 25(2):233-255.
107. Mesulam M.M. The cholinergic innervation of the human cerebral cortex. Prog. Brain Res. 2004, 145(1):67-78.
108. Mesulam M.M., Mufson E.J., Levey A.I., Wainer B.H. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J. Compar. Neurol. 1983, 214(2):170-197.
109. Minton J.A., Tofade T.S., Shah S.A. Psychosis from Anticholinergic medications administered at a smoking cessation clinic. J. Pharm. Pract. 2009, 22(5):489-493. 10.1177/0897190008330201.
110. Mintzer M.Z., Griffiths R.R. Lorazepam and scopolamine: a single-dose comparison of effects on human memory and attentional processes. Exp. Clin. Psychopharmacol. 2003, 11(1):56-72.
111. Mintzer M.Z., Griffiths R.R. Differential effects of scopolamine and lorazepam on working memory maintenance versus manipulation processes. Cogn. Affect. Behav. Neurosci. 2007, 7(2):120-129.
112. Minzenberg M.J., Carter C.S. Developing treatments for impaired cognition in schizophrenia. Trends Cogn. Sci. 2012, 16(1):35-42.
113. Mirza N.R., Peters D., Sparks R.G. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev. 2003, 9(2):159-186.
114. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005, 10(1):79-104.
115. Mueser K.T., McGurk S.R. Schizophrenia. Lancet 2004, 363(9426):2063-2072.
116. Muench J., Hamer A.M. Adverse effects of antipsychotic medications. Am. Fam. Phys. 2010, 81(5):617-622.
117. Mufson E.J., Ginsberg S.D., Ikonomovic M.D., DeKosky S.T. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J. Chem. Neuroanat. 2003, 26(4):233-242.
118. Mullaney I., Dodd M.W., Buckley N., Milligan G. Agonist activation of transfected human M1 muscarinic acetylcholine receptors in CHO cells results in down-regulation of both the receptor and the α subunit of the G-protein G(q). Biochem. J. 1993, 289(1):125-131.
119. Nathan P.J., Watson J., Lund J., Davies C.H., Peters G., Dodds C.M., et al. The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. Int. J. Neuropsychopharmacol. 2013, 16(4):721-731.
120. Navari R.M. Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur. J. Pharmacol. 2014, 722(1):180-186. 10.1016/j.ejphar.2013.08.048.
121. Need A.C., Keefe R.S.E., Ge D., Grossman I., Dickson S., McEvoy J.P., Goldstein D.B. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur. J. Hum. Genet. 2009, 17(7):946-957.
122. Newell K.A., Zavitsanou K., Jew S.K., Huang X.F. Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2007, 31(1):225-233.
123. Nickols H.H., Conn P.J. Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol. Dis. 2014, 61:55-71.
124. Niemi L.T., Suvisaari J.M., Tuulio-Henriksson A., Lönnqvist J.K. Childhood developmental abnormalities in schizophrenia: evidence from high-risk studies. Schizophrenia Res. 2003, 60(2-3):239-258.
125. Nogué S., Sanz P., Munné P., de la Torre R. Acute scopolamine poisoning after sniffing adulterated cocaine. Drug Alcohol Depend. 1991, 27(2):115-116. 10.1016/0376-8716(91)90028-W.
126. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophrenia Res. 2004, 72(1):29-39.
127. Passik S.D., Lundberg J., Kirsh K.L., Theobald D., Donaghy K., Holtsclaw E., et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J. Pain Symptom Manage. 2002, 23(6):526-532. 10.1016/S0885-3924(02)00391-3.
128. Raedler T.J., Knable M.B., Jones D.W., Urbina R.A., Gorey J.G., Lee K.S., et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am. J. Psychiatry 2003, 160(1):118-127.
129. Reichenberg A., Caspi A., Harrington H., Houts R., Keefe R.S.E., Murray R.M., et al. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am. J. Psychiatry 2010, 167(2):160-169.
130. Sarter M., Hasselmo M.E., Bruno J.P., Givens B. Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection. Brain Res. Rev. 2005, 48(1):98-111.
131. Savilla K., Kettler L., Galletly C. Relationships between cognitive deficits, symptoms and quality of life in schizophrenia. Aust. N.Z. J. Psychiatry 2008, 42(6):496-504.
132. Scarr E., Cowie T.F., Kanellakis S., Sundram S., Pantelis C., Dean B. Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol. Psychiatry 2009, 14(11):1017-1023.
133. Scarr E., Craig J.M., Cairns M.J., Seo M.S., Galati J.C., Beveridge N.J., et al. Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA. Trans. Psychiatry 2013, 3(e230):1-9.
134. Scarr E., Keriakous D., Crossland N., Dean B. No change in cortical muscarinic M2, M3 receptors or [35S] GTP(S binding in schizophrenia. Life Sci. 2006, 78(11):1231-1237.
135. Scarr E., Sundram S., Deljo A., Cowie T.F., Gibbons A.S., Juzva S., et al. Muscarinic M1 receptor sequence: preliminary studies on its effects on cognition and expression. Schizophrenia Res. 2012, 138(1):94-98.
136. Scarr E., Sundram S., Keriakous D., Dean B. Altered hippocampal muscarinic M4, but Not M1, receptor expression from subjects with schizophrenia. Biol. Psychiatry 2007, 61(10):1161-1170.
137. Sendt K.V., Tracy D.K., Bhattacharyya S. A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res. 2015, 225(1-2):14-30.
138. Shannon H.E., Bymaster F.P., Calligaro D.O., Greenwood B., Mitch C.H., Sawyer B.D., et al. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. J. Pharmacol. Exp. Ther. 1994, 269(1):271-281.
139. Shannon H.E., Rasmussen K., Bymaster F.P., Hart J.C., Peters S.C., Swedberg M.D.B., et al. Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophrenia Res. 2000, 42(3):249-259. http://dx.doi.org/10.1016/S0920-9964(99)00138-3.
140. Shekhar A., Potter W.Z., Lightfoot J., Lienemann J., Dubé S., Mallinckrodt C., et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry 2008, 165(8):1033-1039.
141. Shirey J.K., Xiang Z., Orton D., Brady A.E., Johnson K.A., Williams R., et al. An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat. Chem. Biol. 2008, 4(1):42-50.
142. Simon A.E., Cattapan-Ludewig K., Zmilacher S., Arbach D., Gruber K., Dvorsky D.N., et al. Cognitive functioning in the schizophrenia prodrome. Schizophrenia Bull. 2007, 33(3):761-771.
143. Sørensen H.J., Sæbye D., Urfer-Parnas A., Mortensen E.L., Parnas J. Premorbid intelligence and educational level in bipolar and unipolar disorders: a Danish draft board study. J. Affect. Disord. 2012, 136(3):1188-1191.
144. Stanhope K.J., Mirza N.R., Bickerdike M.J., Bright J.L., Harrington N.R., Hesselink M.B., et al. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J. Pharmacol. Exp. Ther. 2001, 299(2):782-792.
145. Sur C., Mallorga P.J., Wittmann M., Jacobson M.A., Pascarella D., Williams J.B., et al. N-Desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity. Proc. Nati. Acad. Sci. U.S.A. 2003, 100(23):13674-13679.
146. Swartz M.S., Stroup T.S., McEvoy J.P., Davis S.M., Rosenheck R.A., Keefe R.S.E., et al. What CATIE found: results from the schizophrenia trial. Psychiatr. Serv. 2008, 59(5):500-506.
147. Tabarés-Seisdedos R., Balanzá-Martínez V., Sánchez-Moreno J., Martinez-Aran A., Salazar-Fraile J., Selva-Vera G., et al. Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. J. Affect. Disord. 2008, 109(3):286-299.
148. Tamminga C.A. The neurobiology of cognition in schizophrenia. J. Clin. Psychiatry 2006, 67(9).
149. Tandon R. Antipsychotics in the treatment of schizophrenia: an overview. J. Clin. Psychiatry 2011, 72(Suppl. 1):4-8.
150. Tandon R., DeQuardo J.R., Goodson J., Mann N.A., Greden J.F. Effect of anticholinergics on positive and negative symptoms in schizophrenia. Psychopharmacol. Bull. 1992, 28(3):297-302.
151. Tandon R., Mann N.A., Eisner W.H., Coppard N. Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients. Psychiatry Res. 1990, 31(3):235-241.
152. Tandon R., Shipley J.E., Greden J.F., Mann N.A., Eisner W.H., Goodson J. Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms. Schizophrenia Res. 1991, 4(1):23-30.
153. Thomas D.R., Dada A., Jones G.A., Deisz R.A., Gigout S., Langmead C.J., et al. N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M1 receptor. Neuropharmacology 2010, 58(8):1206-1214.
154. Thomas E., Snyder P.J., Pietrzak R.H., Jackson C.E., Bednar M., Maruff P. Specific impairments in visuospatial working and short-term memory following low-dose scopolamine challenge in healthy older adults. Neuropsychologia 2008, 46(10):2476-2484.
155. Thomas R.L., Langmead C.J., Wood M.D., Challiss R.A.J. Contrasting effects of allosteric and orthosteric agonists on M1 muscarinic acetylcholine receptor internalization and down-regulation. J. Pharmacol. Exp. Ther. 2009, 331(3):1086-1095.
156. Thomsen M., Wess J., Fulton B.S., Fink-Jensen A., Caine S.B. Modulation of prepulse inhibition through both M1 and M4 muscarinic receptors in mice. Psychopharmacology 2010, 208(3):401-416.
157. Tzavara E.T., Bymaster F.P., Davis R.J., Wade M.R., Perry K.W., Wess J., et al. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J. 2004, 18(12):1410-1412.
158. Üçok A., Direk N., Koyuncu A., Keskin-Ergen Y., Yüksel T., Güler J., et al. Cognitive deficits in clinical and familial high risk groups for psychosis are common as in first episode schizophrenia. Schizophrenia Res. 2013, 151(1-3):265-269.
159. Ukai M., Okuda A., Mamiya T. Effects of anticholinergic drugs selective for muscarinic receptor subtypes on prepulse inhibition in mice. Eur. J. Pharmacol. 2004, 492(2-3):183-187. 10.1016/j.ejphar.2004.03.066.
160. Uslaner J.M., Eddins D., Puri V., Cannon C.E., Sutcliffe J., Chew C.S., et al. The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque. Psychopharmacology 2013, 225(1):21-30.
161. Van Oel C.J., Sitskoorn M.M., Cremer M.P.M., Kahn R.S. School performance as a premorbid marker for schizophrenia: a twin study. Schizophrenia Bull. 2002, 28(3):401-414.
162. van Os, Kapur Schizophrenia. Lancet 2009, 374(9690):635-645. 10.1016/S0140-6736(09)60995-8.
163. Vardigan J.D., Cannon C.E., Puri V., Dancho M., Koser A., Wittmann M., et al. Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey. Psychopharmacology 2014.
164. Veroff A.E., Bodick N.C., Offen W.W., Sramek J.J., Cutler N.R. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the computerized neuropsychological test battery (CNTB). Alzheimer Dis. Assoc. Dis. 1998, 12(4):304-312.
165. Vilaró M.T., Palacios JosM., Mengod G. Localization of m5 muscarinic receptor mRNA in rat brain examined by in situ hybridization histochemistry. Neurosci. Lett. 1990, 114(2):154-159.
166. Vinogradov S., Fisher M., Warm H., Holland C., Kirshner M.A., Pollock B.G. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am. J. Psychiatry 2009, 166(9):1055-1062.
167. Volavka J., Czobor P., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J.P., et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry 2002, 159(2):255-262.
168. Weiner D.M., Meltzer H.Y., Veinbergs I., Donohue E.M., Spalding T.A., Smith T.T., et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 2004, 177(1-2):207-216.
169. Wess J. Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Ann. Rev. Pharmacol. Toxicol. 2004, 44:423-450.
170. Wood S.J., Pantelis C., Velakoulis D., Yücel M., Fornito A., McGorry P.D. Progressive changes in the development toward schizophrenia: studies in subjects at increased symptomatic risk. Schizophrenia Bull. 2008, 34(2):322-329.
171. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005, 8(3):457-472. 10.1017/S146114570500516X.
172. Woolley M.L., Carter H.J., Gartlon J.E., Watson J.M., Dawson L.A. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice. Eur. J. Pharmacol. 2009, 603(1-3):147-149.
173. Yeomans J.S. Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology 1995, 12(1):3-16.
174. Zavitsanou K., Katerina Z., Katsifis A., Andrew K., Mattner F., Filomena M., et al. Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 2004, 29(3):619-625. (official publication of the American College of Neuropsychopharmacology).
175. Zavitsanou Katerina, Katsifis Andrew, Yu Yinghua, Huang Xu Feng M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Res. Bull. 2005, 65(5):397-403. doi:.
176. Zeng X.P., Le F., Richelson E. Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur. J. Pharmacol. 1997, 321(3):349-354.
177. Zhang W., Basile A.S., Gomeza J., Volpicelli L.A., Levey A.I., Wess J. Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J. Neurosci. 2002, 22(5):1709-1717.
178. Zorn S.H., Jones S.B., Ward K.M., Liston D.R. Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur. J. Pharmacol.: Mol. Pharmacol. 1994, 269(3):R1-R2.